|
|
|
|
|
|
|
M T Wed Th F |
|
19 August, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
Eli Lilly has a crucial readout coming on a new drug that mimics amylin, and expectations are high. Elizabeth Cairns describes the different classes of these drugs — and why focusing on one receptor may produce better results. |
|
|
|
Karen Weintraub |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Elizabeth Cairns
|
In the amylin race, drug design appears to be a key differentiator. Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug... | |
|
|
|
|
|
|
by Max Gelman
|
The next generation of immunotherapy appears to have arrived. Merck and Moderna on Wednesday said their personalized cancer vaccine, known as intismeran autogene, succeeded in... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Chinese biotech Biokin said its EGFRxHER3 bispecific antibody-drug conjugate passed a late-stage China trial in a genetically-defined form of lung cancer, buoying optimism for a... | |
|
|
|
 |
|
Dario Amodei, co-founder and CEO of Anthropic (Jason Henry/Bloomberg via Getty Images) |
|
|
|
by Andrew Dunn
|
Anthropic’s AI system Claude oversaw a research campaign that designed and generated miniproteins from scratch, the AI lab said in a Tuesday blog post... | |
|
|
|
|
|
